附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012002 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中信建投 医药行业首席分析师 贺菊颖女士 | | 人员姓名 | | | | 时间 | 2020 年 5 月 11 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 、请问公司 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020001 | --- | --- | --- | |----------------|-----------------------------|-----------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 信达证券 医药行业分析师 周贤珮女士 | | 人员姓名 | | | | 时间 | 2020 年 5 月 8 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 、公司总裁 | 2019 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012005 | --- | --- | --- | |----------------|--------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 信达证券 投资经理 孟阳女士 | | | 人员姓名 | | | | 时间 | 2020 年 5 月 27 日 | 14:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 副董事长、董事会秘书赵彩霞女士 | | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | | 1、公司的产品结构 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2012004 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 天风证券 医药行业首席分析师 杨烨辉先生 | | 人员姓名 | | | | 时间 | 2020 年 5 月 13 日 | 16:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 | 1 | 、之前 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020007 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 北京天蝎座资产管理有限公司组织的投资者 | | 人员姓名 | | | | 时间 | 2020 年 8 月 5 日 | 9:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 副董事长、董事会秘书赵彩霞女士 | | 员姓名 | 董事张戈先生 | | | | 证券事务代表庞静杰女士 | | | 投资者关系活动 ...

Financial Performance - In 2019, the company achieved an annual revenue of 860.29 million yuan, a year-on-year increase of 11.09% [3] - The net profit attributable to shareholders was 95.80 million yuan, with a year-on-year growth of 109.85% [4] - In Q1 2020, the company reported a revenue of 218.05 million yuan, a year-on-year increase of 16.34% [4] - The net profit attributable to shareholders for Q1 2020 was 44.13 million yuan, showing a year-on-year increase of 226.07% [4] - For the first half of 2020, the expected net profit attributable to shareholders is between 81.31 million yuan and 96.94 million yuan, representing a year-on-year growth of 160%-210% [5] Strategic Initiatives - The company focuses on four exclusive medical insurance pillar products to drive sales growth [5] - Emphasis on digital transformation and refined management to enhance operational efficiency [12] - The company has adopted a multi-channel marketing strategy, including professional clinical promotion, agency recruitment, and OTC retail [9][10] Market Opportunities - The company capitalized on policy opportunities related to chronic disease medications, particularly during the pandemic [4][11] - The removal of the "△" mark from the medical insurance directory for certain products has opened new market opportunities [18] - The market for the company's products, especially 荷丹片/胶囊, is expected to grow significantly due to its potential user base among patients with high blood pressure, blood sugar, and cholesterol [17][18] Cost Management - The company has implemented measures to reduce marketing costs while increasing efficiency through digital channels [12][14] - Sales expenses are projected to slightly increase in Q2 2020 compared to Q1 but will still show a year-on-year decline [14] Future Outlook - The company aims to maintain steady revenue growth through its established marketing system and product structure [15] - Plans for potential mergers and acquisitions focus on introducing unique traditional Chinese medicine products that align with existing offerings [19]

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020008 | --- | --- | --- | --- | |----------|--------------------------------|-------|---------------------------------------------------------| | | | | | | 投资者关 | | | 特定对象调研 □分析师会议 | | 系活动类 | □媒体采访 □业绩说明会 | | | | 别 | □ 新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □ | | 其他 （请文字说明其他活动内容） | | 参与单位 | 华融证券 医药行业分析师 张科然 | | | | 名称及人 | 华泰证券 研究员 张云逸 | | | | 员姓名 | | | | | 时间 | 2020 年 9 月 14 日 | | 13:00 | | 地点 | | | 辽宁康辰药业有限公司 厂区及会议室 | | 上市公司 | | | 董事会执行委员会 ...

附件二：投资者关系活动记录表格式 证券代码：002107 证券简称：沃华医药 山东沃华医药科技股份有限公司投资者关系活动记录表 编号：2020009 | --- | --- | --- | |----------|------------------------------|---------------------------------------------| | | | | | 投资者关 | | 特定对象调研 □分析师会议 | | 系活动类 | □媒体采访 □业绩说明会 | | | 别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位 | | 民生证券 综合金融部 副总经理 蔡宏宇 | | 名称及人 | | 渤海汇金 私募投资部 高级投资经理 纪纲 | | 员姓名 | | 渤海人寿保险 资产管理中心 高级研究员 郑森峰 | | | | 华商基金 研究发展部 行业研究员 庄嘉赟 | | | | 开源证券 研究所 医药行业研究员 王斌 | | 时间 | 2020 年 9 月 23 日 | 14:00 | | 地点 | 公 ...

1 证券代码：002107 证券简称：沃华医药 公告编号：2022-031 山东沃华医药科技股份有限公司 关于参加山东辖区上市公司 2022 年度投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为进一步增强与广大投资者的沟通互动，构建和谐投资者关系， 切实提高上市公司透明度、规范运作和治理水平，山东沃华医药科技 股份有限公司（以下简称公司）将于 2022 年 11 月 16 日（星期三） 下午 14:00 参加山东证监局、山东上市公司协会联合举办的"山东辖 区上市公司 2022 年度投资者网上集体接待日"活动，现将有关事项 公告如下： 一、活动时间 2022 年 11 月 16 日（星期三）14:00-16:00 二、活动方式 本次集体接待日活动将采取网络远程的方式举行，投资者可以登 录全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次活动。 三、参加人员 公司副董事长、董事会秘书赵彩霞女士和副总裁、财务总监王炯 先生将通过网络在线交流形式与投资者就公司治理、经营状况、发展 战略、三季度报告等投资者关注的 ...

Financial Performance - The company's revenue for Q3 2022 was ¥249,252,514.10, representing a 27.24% increase year-over-year[3] - The net profit attributable to shareholders decreased by 34.29% to ¥23,039,022.71 for the same period[3] - The net profit after deducting non-recurring gains and losses was ¥22,346,330.15, down 25.51% compared to the previous year[3] - The basic earnings per share for Q3 2022 was ¥0.04, a decrease of 33.33% year-over-year[3] - The net profit for Q3 2022 was CNY 63,423,848.29, a decrease of 54.7% compared to CNY 140,071,875.08 in Q3 2021[20] - The total profit for Q3 2022 was CNY 73,543,783.99, down 53% from CNY 156,272,539.12 in the same period last year[20] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.14, compared to CNY 0.24 in Q3 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,106,280,996.04, a decrease of 4.72% from the end of the previous year[4] - The total assets as of September 30, 2022, were CNY 1,106,280,996.04, down from CNY 1,161,092,124.65 at the beginning of the year[17] - The total liabilities increased to CNY 273,468,562.66 from CNY 231,829,043.56, representing a rise of 17.9%[16] - The equity attributable to shareholders decreased to CNY 749,762,369.72 from CNY 820,716,496.07, a decline of 8.6%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥122,443,327.65, down 16.07% compared to the same period last year[8] - Cash flow from operating activities for the period was CNY 145,888,137.53, an increase of 19.2% from CNY 122,443,327.65 in the previous year[22] - The company reported a cash outflow from investing activities of CNY 2,159,798.66, an improvement from CNY 17,067,912.78 in the previous year[23] - The company’s cash outflow from financing activities was CNY 159,874,496.00, a decrease from CNY 343,690,720.26 in the previous year[23] - The company's cash and cash equivalents as of September 30, 2022, were CNY 288,640,415.39, a decrease from CNY 326,843,819.45 at the beginning of the year[14] - Cash and cash equivalents at the end of Q3 2022 were CNY 286,622,251.48, compared to CNY 273,990,376.80 at the end of Q3 2021[23] Operational Metrics - The total operating revenue for the third quarter of 2022 was CNY 752,849,548.28, an increase of 5.5% compared to CNY 711,073,285.71 in the same period last year[19] - The total operating costs for the third quarter of 2022 amounted to CNY 676,541,958.15, up 19.7% from CNY 564,970,625.95 in the previous year[19] - The total operating income for Q3 2022 was CNY 74,736,005.11, down from CNY 157,662,189.67 in Q3 2021[20] - The company reported a net profit margin decrease due to rising costs, impacting overall profitability[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,770[10] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., held 50.27% of the shares[10] Other Financial Information - The company reported a significant increase in accounts payable by 57.68% to ¥40,310,546.45 due to increased material procurement[7] - Accounts receivable increased to CNY 111,355,562.21 from CNY 93,319,711.03 at the start of the year, reflecting a growth of 19.4%[14] - Inventory decreased to CNY 144,317,353.40 from CNY 165,911,355.62, indicating a reduction of 13.0%[15] - Research and development expenses for the third quarter were CNY 38,274,932.52, slightly down from CNY 40,069,849.45 in the previous year[19] - The company incurred a total of CNY 1,324,177.32 in non-operating expenses during Q3 2022[20] - The company did not report any net profit from subsidiaries under common control during the period[21]